Pricing Log in Create free account
Saturday 17 October 2026 Export NBTX’s income statement to Excel — free account

Nanobiotix S.A. - Sponsored ADR

NBTX Healthcare Biotechnology

21.30 0.93 −4.18%
Market cap
$1.1B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
3.40
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 1,130.00
Revenue 0.10
Net Income (130.50)
Free Cash Flow (87.24)
Net Debt (128.93)
Current Ratio 1.44
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E —
P/S ratio 4,254.38 (above 10: high)
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth (6.16%) (below 0%: weak)
Next Y EPS Growth 63.63% (at or above 15%: strong)
Next Y revenue growth —
Next 5Y EPS Growth 30.10% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3,499×, against a ten-year median of 1,146×; over the ten years it ranged from 301× in 2022 to 7,977× in 2026.
P/S against its own 10 years 85.15%
10-year low 10-year high
EV/Sales against its own 10 years 82.15%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 81 54 60 129
Receivables 1 3 2 2
Inventory — — — —
Other 12 9 9 12
95 67 71 144
2023 2024 2025 Q'26
Payables 20 22 10 10
ST’ Debt — — — —
Other 34 42 55 90
54 64 65 100

Compound Annual Growth %

10y 5y 3y
Sales — 66.64% 94.24%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — 37
’24 — — — — —
’23 — — — — 39
’22 — — — — 5
’21 — — — — 3
’20 — — — — 3
Fiscal quarters ending in the months shown.
value withheld pending a data check

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — (38)
’24 — — — — (21)
’23 — — — — (14)
’22 — — — — (39)
’21 — — — — (35)
’20 — — — — (31)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — (20) — (38) (38)
’24 — (7) — (22) (22)
’23 — (19) — (14) (14)
’22 — (19) — (39) (39)
’21 — (18) — (36) (36)
’20 — (14) — (32) (32)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — (0.57)
’24 — — — — (1.56)
’23 — — — — (1.17)
’22 — — — — (1.76)
’21 — — — — (1.60)
’20 — — — — (1.60)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — 15.89 6.51 2.32 1.75 2.76 2.82

Analyst estimates 2026–2028

Powerpack
High — — — — 21.55 20.63 10.42 11.00 8.96 30.35
People
People Employees — — — 90 88 100 102 102 108 97
Revenue/emp, $m 0.00 0.00 0.00 0.03 0.03 0.03 0.05 0.38 (0.07) 0.38
Income, $m
Income, $m Revenue 2 0 0 3 3 3 5 39 — 37
Gross margin, % 0.00 (37.14) 0.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
EBT (27) (35) (39) (57) (38) (56) (60) (43) (74) (27)
EBT margin, % (1,636.19) (11,667.74) (28,962.07) (2,003.63) (1,336.80) (1,775.50) (1,194.12) (109.32) 946.06 (73.51)
Net income (23) 0 (35) (57) (38) (56) (60) (43) (74) (27)
Depreciation 1 0 1 2 2 2 2 2 2 2
Per share, $
Per share, $ Revenue 0.11 0.02 0.01 0.13 0.12 0.09 0.14 1.06 (0.16) 0.77
Earnings (1.51) (1.81) (1.78) (2.63) (1.60) (1.60) (1.76) (1.17) (1.56) (0.57)
Cash flow (1.26) (1.46) (1.13) (2.13) (1.29) (1.02) (1.12) (0.37) (0.45) (0.79)
Capex 0.00 0.00 0.00 (0.07) 0.00 (0.01) 0.00 (0.01) (0.02) (0.01)
Free cash flow (1.26) (1.46) (1.13) (2.21) (1.29) (1.03) (1.12) (0.38) (0.47) (0.80)
Book value 1.18 3.01 0.61 (0.10) 3.30 0.91 (0.82) (0.05) (1.50) (2.00)
Shares, m 15 17 27 22 24 35 35 37 47 48
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 2,115.07 2,115.07 2,115.07 2,115.07 2,557.11 1,617.86 741.02 1,468.06 573.24 4,617.90
P/B 0.00 0.00 0.00 0.00 4.27 5.33 0.00 0.00 0.00 0.00
EV/Sales 2,239.44 2,239.44 2,239.44 2,239.44 1,917.58 1,146.44 803.15 1,167.28 537.50 4,526.00
EV/FCF (3.81) (3.81) (3.81) (3.81) (2.22) (1.20) (0.75) (1.34) (0.91) (5.41)
Cash, $m
Cash, $m Operating cash flow (19) (25) (30) (46) (31) (35) (39) (14) (21) (38)
Capex 0 (2) (1) (2) 0 0 0 0 (1) (1)
Free cash flow (19) (25) (30) (48) (32) (36) (39) (14) (22) (38)
Balance, $m
Balance, $m Working capital 20 53 36 36 121 67 15 41 3 6
Total debt 6 6 24 50 60 52 57 — — —
Net debt (16) (51) (18) (39) (136) (99) (44) (81) (54) (60)
Shareholders’ equity 18 53 16 (2) 80 32 (28) (2) (71) (96)
Returns, %
Returns, % ROA (45.76) (198.42) (82.41) (98.45) (35.52) (40.66) (65.55) (52.21) (84.46) (36.24)
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE (65.20) (89.17) (101.46) (812.85) (97.94) (99.13) (3,754.04) 281.84 201.73 32.53
Negative figures in brackets.
value withheld pending a data check

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2019 · fundamentals updated 28 Sep 2026

Charts ten years each

Nanobiotix S.A. - Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
DRTS Alpha Tau Medical Ltd. $1.2B — (loss-making) — — n/m −30.42% (below 0%: shrinking) 0.00% 0.00% Compare
LBRX LB Pharmaceuticals Inc $1.2B — (loss-making) — — n/m −579.03% (below 0%: shrinking) — 0.00% Compare
BCAX Bicara Therapeutics Inc. $1.2B — (loss-making) — — n/m −72.95% (below 0%: shrinking) — 0.00% Compare
DMRA Galecto, Inc. $1.2B — (loss-making) — — n/m −877.51% (below 0%: shrinking) 0.00% 0.00% Compare
VOR Vor Biopharma Inc. $1.1B — (loss-making) — — n/m −47.59% (below 0%: shrinking) 0.00% — Compare
NBTX Nanobiotix S.A. - Sponsored ADR $1.1B — (loss-making) — −71.69% (below 0%: shrinking) n/m −177.26% (below 0%: shrinking) 0.00% 0.00%
REPL Replimune Group, Inc. $1.1B — (loss-making) — — n/m +5.04% (above 0%: growing) 0.00% 0.00% Compare
IMTX Immatics N.V. $1.1B — (loss-making) — (loss-making) +97.71% (above 0%: growing) n/m −44.41% (below 0%: shrinking) 100.00% (734.95%) Compare
JANX Janux Therapeutics, Inc. $1.1B — (loss-making) — (loss-making) +2,238.72% (above 0%: growing) n/m +150.57% (above 0%: growing) 100.00% (308.66%) Compare
Median of peers $1.2B — — — — −46.00% 0.00% 0.00%

All 614 Biotechnology stocks →

Nanobiotix S.A. - Sponsored ADR (NBTX) key facts

  • Nanobiotix S.A. - Sponsored ADR (NBTX) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
  • As of October 16, 2026, NBTX traded at $21.30, a market capitalization of $1.1 billion.
  • Return on equity was 32.5% and debt-to-equity 0.00.
  • Its Altman Z-score is 3.40 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Sep 28, 2026.

Nanobiotix S.A. - Sponsored ADR (NBTX) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/NBTX · Data as of Sep 28, 2026 · For information only; not investment advice. · © 2026 stockrow.com